search
Back to results

Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome

Primary Purpose

Heart Failure

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Performance of WHEELS-I in promoting DASH/SRD adoption
Effects of a 2-week DASH/SRD intervention vs. control diet on HFpEF functional cardiovascular risk factors
Sponsored by
VA Office of Research and Development
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Heart Failure focused on measuring obesity, sodium, DASH diet, hypertension, vascular stiffness, diastolic function

Eligibility Criteria

45 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Veterans aged 45 years with HTN

    • here defined as screening systolic BP 130 and/or diastolic BP 85 mmHg, or current use of anti-hypertensive drugs
  • and metabolic syndrome

    • body mass index 30 kg/m2 and/or waist circumference >94 cm
  • Participants must also be willing to participate in the WHEELS-I program by using a smartphone application or email

Exclusion Criteria:

  • On-treatment systolic BP of >160 mmHg at screening visit
  • previous history of HF
  • left ventricular ejection fraction <50%
  • moderate or severe valvular heart disease
  • myocardial infarction or stroke within the prior 6 months
  • chronic kidney disease with estimated glomerular filtration rate <45 ml/min/ 1.73m2
  • unoperated aortic aneurysm for which surgery is indicated, prior hyperkalemia requiring urgent treatment
  • hemoglobin <9 gm/dL
  • investigator-determined factors: severe pulmonary disease, e.g.:

    • oxygen-requiring
  • hepatic disease, e.g.:

    • cirrhosis
  • severely uncontrolled diabetes (hemoglobin A1c >10%)
  • active cancer other than non-melanoma skin or low-risk prostate cancer
  • other comorbidity with expected survival <12 months
  • active alcohol/illicit substance abuse
  • and/or a history of persistent nonadherence to treatment
  • Veterans involved in another study (unless it is survey-only and the other investigator will allow us to invite the person in a survey-only study to consider our study)

Sites / Locations

  • VA Ann Arbor Healthcare System, Ann Arbor, MIRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Experimental

Placebo Comparator

Arm Label

Motivational Interviewing + WHEELS-I

Motivational Interviewing

DASH/SRD Diet

Control Diet

Arm Description

In addition to motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan., participants in this arm will also receive an electronically-delivered tailored messaging intervention called Women's and Men's Hypertension Experiences and Emerging Lifestyle Intervention (WHEELS-I).

Participants in this arm will receive motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan.

Participants in this arm will receive prepared, pre-packaged meals containing 1150mg of sodium.

Participants in this arm will receive prepared, pre-packaged meals containing 5750mg of sodium.

Outcomes

Primary Outcome Measures

Carotid-femoral pulse wave velocity
Velocity of pulse wave traveling between carotid and femoral artery; validated measure of arterial stiffness
Left ventricular mass index
Left ventricular mass indexed to height

Secondary Outcome Measures

Ventricular stiffness
Ventricular stiffness k, by Parametrized Diastolic Formalism analysis
Global longitudinal left ventricular strain
Global longitudinal left ventricular strain, a sensitive measure of ventricular systolic function
Global left atrial strain
Global left atrial strain, a novel measure of atrial function
Carotid-femoral pulse wave velocity
Velocity of pulse wave traveling between carotid and femoral artery; validated measure of arterial stiffness
Left atrial volume
Left atrial volume by 3D echocardiography

Full Information

First Posted
May 26, 2017
Last Updated
January 4, 2023
Sponsor
VA Office of Research and Development
search

1. Study Identification

Unique Protocol Identification Number
NCT03170375
Brief Title
Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome
Official Title
Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 2, 2019 (Actual)
Primary Completion Date
December 30, 2023 (Anticipated)
Study Completion Date
December 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Tens of thousands of Veterans have heart failure with preserved ejection fraction (HFpEF), and suffer poor quality of life, frequent hospitalizations, and high death rates. Older Veterans and those with high blood pressure, obesity, and the metabolic syndrome (abnormal cholesterol and resistance to insulin's effects) are particularly at risk for HFpEF. However, it is not clear why only some Veterans in this risk group eventually develop HFpEF. Extensive information from experimental animal models and some human studies suggests that dietary patterns in vulnerable 'salt-sensitive' people could contribute to the risk for HFpEF. Reducing salt intake and increasing overall dietary quality in at-risk Veterans could prevent heart and blood vessel damage that ultimately leads to HFpEF. Reducing the development of HFpEF, which currently has no definitive treatment, is highly relevant to the VA's mission to emphasize prevention of disease and population health.
Detailed Description
COVID-19 in-person visit hold has been removed- screening and actively enrolling. We are not currently performing sublingual darkfield microscopy because of the need for close face-to-face contact with an open-mouthed patient for several minutes in the setting of COVID-19 pandemic. Patients with heart failure (HF) account for over 1,200,000 VA outpatient visits per year, and HF remains the most common cause for hospital admission in the VA. Approximately 1/3 of Veterans with HF have 'preserved' ejection fraction (HFpEF), or relatively normal contractile function of the heart; such patients suffer functional decline and poor quality of life, and half die within 5 years after diagnosis. Risk factors for developing HFpEF are more common in Veterans than the general population, and the burden of HFpEF to the VA system will rise in the years ahead as these Veterans age. Preventive efforts are critical, but are hampered by gaps in knowledge related to HFpEF pathophysiology. The long term goal of this proposal is to prevent the onset of HFpEF in at-risk Veterans. Hypertension (HTN) confers the highest population-attributable risk for HFpEF, particularly when accompanied by the metabolic syndrome, a constellation of obesity, insulin resistance, and dyslipidemia. Animal models of HTN and metabolic syndrome develop HFpEF due to microvascular oxidative stress and inflammation induced by high sodium intake. Recent data from cardiac biopsies confirm similar mechanisms in human HFpEF. Dietary sodium restriction is widely recommended to prevent HTN-associated heart disease in humans, but this advice is now controversial. Few studies have examined how individual differences in response to sodium intake affect risk. "Salt-sensitive" persons have blood pressure (BP) that changes in parallel with sodium intake, and commonly develop cardiovascular abnormalities associated with HFpEF. The overall objective of this proposal is to evaluate salt-sensitivity as a novel, diet-responsive risk factor for incident HFpEF in Veterans with HTN and metabolic syndrome. The central hypothesis is that the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating pattern will improve cardiovascular functional and structural risk factors for HFpEF in Veterans with the salt-sensitive phenotype. Guided by findings in experimental models, cohort studies, and strong preliminary evidence from the investigators' research group, this hypothesis will be tested in a two-phase study and by pursuing three specific aims: 1) Determine effects of DASH/SRD on functional and structural cardiovascular HFpEF risk factors in salt-sensitive vs. salt-resistant Veterans, 2) measure the effect of an electronically-delivered tailored-messaging intervention on DASH/SRD adherence, and 3) determine effects of DASH/SRD intervention and adoption on microvascular function and assess the endothelial glycocalyx as a biomarker of cardiovascular response to DASH/SRD. Phase 1 of the study is a crossover-randomized comparison of DASH/SRD vs. control diet for two weeks each, and Phase 2 a 6-month extension to promote DASH/SRD adherence. The salt-sensitive phenotype will be defined by between-diet changes in 24-hour mean BP during Phase 1. In Phase 2, the efficacy of motivational interviewing-based counseling and the Women's and Men's Hypertension Experiences and Emerging Lifestyles Intervention (WHEELS-I), a tailored messaging program, to sustain DASH/SRD adherence, will be compared. Echocardiography and arterial tonometry will be used to assess HFpEF-related cardiovascular parameters during short- and longer-term dietary modification and their interaction with salt-sensitivity. In vivo microscopy and novel blood testing will assess microvascular function and the integrity of the endothelial glycocalyx, a blood vessel lining that is sodium-responsive and may mediate the adverse effects of salt-sensitivity. This proposal is innovative because it represents the first study to examine salt-sensitivity as a factor promoting HFpEF in Veterans with HTN and metabolic syndrome, the highest risk group for incident HFpEF. Moreover, it aims to link microvascular dysfunction, an important pathway in human HFpEF, with endothelial glycocalyx damage, a potential biomarker for sodium-mediated vascular risk. The proposed research is significant because it will vertically advance the investigators' understanding of how dietary factors contribute to the pathophysiology of HFpEF, a major and growing health threat to Veterans.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure
Keywords
obesity, sodium, DASH diet, hypertension, vascular stiffness, diastolic function

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
Phase 1 of study: randomized crossover design, 14 days each of control vs. sodium-restricted DASH diet Phase 2 of study: randomized assignment, 6 months of motivational interviewing vs. motivational interviewing plus mobile application-based promotion of dietary adherence
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
130 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Motivational Interviewing + WHEELS-I
Arm Type
Experimental
Arm Description
In addition to motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan., participants in this arm will also receive an electronically-delivered tailored messaging intervention called Women's and Men's Hypertension Experiences and Emerging Lifestyle Intervention (WHEELS-I).
Arm Title
Motivational Interviewing
Arm Type
Active Comparator
Arm Description
Participants in this arm will receive motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan.
Arm Title
DASH/SRD Diet
Arm Type
Experimental
Arm Description
Participants in this arm will receive prepared, pre-packaged meals containing 1150mg of sodium.
Arm Title
Control Diet
Arm Type
Placebo Comparator
Arm Description
Participants in this arm will receive prepared, pre-packaged meals containing 5750mg of sodium.
Intervention Type
Behavioral
Intervention Name(s)
Performance of WHEELS-I in promoting DASH/SRD adoption
Other Intervention Name(s)
Phase 2
Intervention Description
Participants will receive the WHEELS-I electronically-delivered tailored messaging intervention in addition to motivational interviewing-based counseling.
Intervention Type
Behavioral
Intervention Name(s)
Effects of a 2-week DASH/SRD intervention vs. control diet on HFpEF functional cardiovascular risk factors
Other Intervention Name(s)
Phase 1
Intervention Description
Participants will be randomized to the sequence DASH/SRD-control diet or control diet-DASH/SRD, and consume the diets for 14 days each.
Primary Outcome Measure Information:
Title
Carotid-femoral pulse wave velocity
Description
Velocity of pulse wave traveling between carotid and femoral artery; validated measure of arterial stiffness
Time Frame
Phase 1 of study, change from baseline at the end of week 2 and week 4
Title
Left ventricular mass index
Description
Left ventricular mass indexed to height
Time Frame
Phase 2 of study, change from baseline to 6 months
Secondary Outcome Measure Information:
Title
Ventricular stiffness
Description
Ventricular stiffness k, by Parametrized Diastolic Formalism analysis
Time Frame
Phase 1 of study, change from baseline at the end of week 2 and week 4
Title
Global longitudinal left ventricular strain
Description
Global longitudinal left ventricular strain, a sensitive measure of ventricular systolic function
Time Frame
Phase 1 of study, change from baseline at the end of week 2 and week 4
Title
Global left atrial strain
Description
Global left atrial strain, a novel measure of atrial function
Time Frame
Phase 1 of study, change from baseline at the end of week 2 and week 4
Title
Carotid-femoral pulse wave velocity
Description
Velocity of pulse wave traveling between carotid and femoral artery; validated measure of arterial stiffness
Time Frame
Phase 2 of study, change from baseline to 6 months
Title
Left atrial volume
Description
Left atrial volume by 3D echocardiography
Time Frame
Phase 2 of study, change from baseline to 6 months
Other Pre-specified Outcome Measures:
Title
Salt-sensitivity phenotype
Description
Change in 24-hour mean of >= 8 mmHg will define the salt-sensitive blood pressure phenotype
Time Frame
Phase 1 of study, change from baseline at the end of week 2 and week 4
Title
24-hour urinary sodium excretion
Description
Measure of dietary sodium intake
Time Frame
Phase 2 of study, change from baseline to 6 months
Title
Sodium-restricted DASH diet adherence
Description
Sodium-restricted DASH diet score on Food Frequency Questionnaire, measured by complete or partial adherence to 9 dietary domains
Time Frame
Phase 2 of study, change from baseline to 6 months
Title
Sodium-restricted DASH diet adherence
Description
Analysis of 3-day food diaries by a Registered Dietitian, utilizing the Nutrition Data System for Research
Time Frame
Phase 2 of study, months 1 and 6

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Veterans aged 45 years with HTN here defined as screening systolic BP 130 and/or diastolic BP 85 mmHg, or current use of anti-hypertensive drugs and metabolic syndrome body mass index 30 kg/m2 and/or waist circumference >94 cm Participants must also be willing to participate in the WHEELS-I program by using a smartphone application or email Exclusion Criteria: On-treatment systolic BP of >160 mmHg at screening visit previous history of HF left ventricular ejection fraction <50% moderate or severe valvular heart disease myocardial infarction or stroke within the prior 6 months chronic kidney disease with estimated glomerular filtration rate <45 ml/min/ 1.73m2 unoperated aortic aneurysm for which surgery is indicated, prior hyperkalemia requiring urgent treatment hemoglobin <9 gm/dL investigator-determined factors: severe pulmonary disease, e.g.: oxygen-requiring hepatic disease, e.g.: cirrhosis severely uncontrolled diabetes (hemoglobin A1c >10%) active cancer other than non-melanoma skin or low-risk prostate cancer other comorbidity with expected survival <12 months active alcohol/illicit substance abuse and/or a history of persistent nonadherence to treatment Veterans involved in another study (unless it is survey-only and the other investigator will allow us to invite the person in a survey-only study to consider our study)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lauren E Herty, MPH RD
Phone
(734) 222-7490
Email
Lauren.Herty@va.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Scott L Hummel, MD
Email
Scott.Hummel@va.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Scott L. Hummel, MD
Organizational Affiliation
VA Ann Arbor Healthcare System, Ann Arbor, MI
Official's Role
Principal Investigator
Facility Information:
Facility Name
VA Ann Arbor Healthcare System, Ann Arbor, MI
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48105
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lauren E Herty, MPH RD
Phone
734-222-7490
Email
Lauren.Herty@va.gov
First Name & Middle Initial & Last Name & Degree
Scott L Hummel, MD
Email
Scott.Hummel@va.gov
First Name & Middle Initial & Last Name & Degree
Scott L. Hummel, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome

We'll reach out to this number within 24 hrs